Sanofi India Declares ₹75 Interim Dividend; Q3 PAT Up 54%

Sanofi India Limited announced its unaudited financial results for the quarter and nine months ended September 30, 2026. The company reported a domestic net sales growth of 2% and total net sales growth of 4% compared to Q3 2025. Profits before tax and exceptional items rose to INR 158 crores from INR 130 crores in Q3 2025, with profit before tax as a percentage of net sales improving to 34%. The company declared an interim dividend of ₹75 per equity share and fixed November 5, 2026, as the record date. The diabetes business showed strong momentum, with the insulin portfolio growing by 9% and a 55% market share in the diabetes injectable segment. Public sector business surged by 85%. Sanofi India also highlighted its CSR initiatives, including the KiDS Program and Medical Mobile Units.